Figure 4.

IFP35 was released in vitro and in vivo upon virus infection

(A and B) IFP35 (A) and IL-6 (B) in the sera of hACE2 mice 4 days after SARS-CoV-2 (5LD₅₀, 1.5 × 10⁵ tissue culture infectious dose 50 [TCID₅₀]/50 μL) infection; n = 5.

(C and D) IFP35 (C) and IL-6 (D) in the sera of C57BL/6J mice 3 days after PR8 (2LD₅₀, 2 × 10⁶ PFU) infection; n = 3.

(E and F) IFP35 released by A549 (E) and RAW264.7 (F) cells, stimulated by PR8 (5 MOI). LPS (100 ng/mL) and PBS were used as positive and negative control, respectively.

Data are mean values ± SEM. Significance in (A)–(D) was analyzed using unpaired Student’s t test. Significance of (E) and (F) was conducted by multiple-comparisons one-way analysis of variance (ANOVA). ^∗p < 0.05, ^∗∗p < 0.01, ^∗∗∗p < 0.001.